San Diego
,
US
1 - 4 December 2025
Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)
Presentation schedule and materials
Monday, 01 December 2025
15:00
- 17:30
PT
P091
POSTER
Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer’s Disease After 12 Weeks of Subcutaneous Treatment
Peter Johannsen1; Marie Aare Bentsen1; Dylan Matthew Belmont‑Rausch1; Lisbeth Carstensen1; Rose Jeppesen1; Gabriel Martino1; Martí Jiménez-Mausbach1; Anne Börjesson-Hanson2,3; Lotte Bjerre Knudsen1
MATERIALS AVAILABLE
Tuesday, 02 December 2025
09:15
- 09:40
PT
ORAL PRESENTATION
From real-world data to clinical trials: The case for investigating semaglutide in Alzheimer’s disease
Peter Johannsen1
MATERIALS AVAILABLE
Wednesday, 03 December 2025
07:15
- 17:30
PT
#00169
POSTER
Semaglutide impacts proteomic signatures related to dementia risk in the SELECT cardiovascular outcomes trial
Martí Jiménez-Mausbach1; Jan Christian Refsgaard1; Gabriel Martino1; Teresa Leon Colombo1; Betty Tijms2; Clare Paterson3
MATERIALS AVAILABLE
17:05
- 17:45
PT
ORAL PRESENTATION
evoke and evoke+: Two phase 3 randomised placebo-controlled trials of semaglutide in participants with early-stage Alzheimer’s disease (NCT04777396 and NCT04777409)
Jeffrey L. Cummings1; Alireza Atri2,3,4; Howard H. Feldman5; Mary Sano6,7; Henrik Zetterberg8; Filip K. Knop9; Peter Johannsen9; Teresa León9; Rikke Mortensen Abschneider9; Philip Scheltens10,11
MATERIALS AVAILABLE
Thursday, 04 December 2025
07:15
- 17:00
PT
P362
POSTER
Medication Adherence and Cost of Care for Comorbid Conditions in Patients with Early Alzheimer's Disease: A Retrospective Cohort Study Using the Axon Registry and Claims Data
Lei Lv1; Abdalla Aly1; Caroline McKay1; Paul Mystkowski1; Shannon Gallagher2; Kristian Garcia2; Heather E. Moss2,3; Soeren Mattke4
MATERIALS AVAILABLE
14:25
- 14:40
PT
OC33
ORAL PRESENTATION
Effects of Semaglutide on Alzheimer’s Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment
Kristian Steen Frederiksen1,2; Marie Aare Bentsen3; Dylan Matthew Belmont-Rausch3; Lisbeth Carstensen3; Brian Cutler4; Redwan Farooq4; Lea Hildebrandt3; Martí Jiménez-Mausbach3; Peter Johannsen3; Gabriel Martino3; Joseph Polex-Wolf3; Amaya Zaratiegui3; Giovanni B. Frisoni5,6; Kathrine E. Attfield4; Lotte Bjerre Knudsen3
MATERIALS AVAILABLE
Keywords